A systematic review of the last two decades of NK cell-based clinical trials: state of the art of AML therapy.
Bakhtiyaridovvombaygi M, Kheyrandish S, Safdari SM, Eskandrian S, Rousta H, Hossaini D, Rastgar A, Yazdanparast S, Firuzpour F, Shabihi N, Izadpanah A, Parkhideh S, Roshandel E, Hajifathali A, Gharehbaghian A.
Bakhtiyaridovvombaygi M, et al.
BMC Cancer. 2025 Sep 30;25(1):1461. doi: 10.1186/s12885-025-14837-y.
BMC Cancer. 2025.
PMID: 41029201
Free PMC article.
Peripheral blood (PB)-derived NK cells were the main source (82%), with purification methods mainly using CliniMACS-based CD3 depletion and CD56 selection. Short-term activation ( 24 h) and long-term expansion (> 7 days) were employed in 36% of studies each. In non-HSC …
Peripheral blood (PB)-derived NK cells were the main source (82%), with purification methods mainly using CliniMACS-based CD3 depletion and …